(Q37944321)

25 August 2017

Innate immune recognition of poxviral vaccine vectors (English)

1 reference

25 August 2017

Michael P Brown

3

0 references

John D. Hayball

object named as

John D Hayball

series ordinal

4

0 references

author name string

Erin L Lousberg

series ordinal

1

1 reference

PubMed ID

21988308

25 August 2017

Kerrilyn R Diener

series ordinal

2

1 reference

25 August 2017

1 October 2011

1 reference

Expert Review of Vaccines

25 August 2017

1 reference

25 August 2017

10

1 reference

25 August 2017

1435-1449

1 reference

25 August 2017

10

1 reference

Poxviruses as vaccine vectors

25 August 2017

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Poxviruses as expression vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Smallpox vaccines: Past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Cytokine expression patterns associated with systemic adverse events following smallpox immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Smallpox vaccination and bioterrorism with pox viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

NYVAC: a highly attenuated strain of vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The genome of canarypox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Comparative Efficacies of Three Commercially Available Vaccines against West Nile Virus (WNV) in a Short-Duration Challenge Trial Involving an Equine WNV Encephalitis Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Development of a cytomegalovirus vaccine: lessons from recent clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Therapeutic vaccines against melanoma and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Construction of recombinant fowlpox viruses as vectors for poultry vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Protective immunity against avian influenza induced by a fowlpox virus recombinant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Recombinant fowlpox virus inducing protective immunity in non-avian species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Influence of IFNgamma co-expression on the safety and antiviral efficacy of recombinant fowlpox virus HIV therapeutic vaccines following interruption of antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Randomized, placebo-controlled, phase I/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Toll-like receptor 2 on inflammatory monocytes induces type I interferon in response to viral but not bacterial ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Evaluating vaccinia virus cytokine co-expression in TLR GKO mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

A critical role for direct TLR2-MyD88 signaling in CD8 T-cell clonal expansion and memory formation following vaccinia viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The adaptor molecule MyD88 directly promotes CD8 T cell responses to vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Toll-like receptor 8-mediated activation of murine plasmacytoid dendritic cells by vaccinia viral DNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Recognition of vaccinia virus-infected cells by human natural killer cells depends on natural cytotoxicity receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Modified vaccinia virus Ankara induces Toll-like receptor-independent type I interferon responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

RNA species generated in vaccinia virus infected cells activate cell type-specific MDA5 or RIG-I dependent interferon gene transcription and PKR dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Antigen-specific T-cell responses to a recombinant fowlpox virus are dependent on MyD88 and interleukin-18 and independent of Toll-like receptor 7 (TLR7)- and TLR9-mediated innate immune recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

A46R and A52R from vaccinia virus are antagonists of host IL-1 and toll-like receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Poxviral regulation of the host NF-kappaB response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus lacking the Bcl-2-like protein N1 induces a stronger natural killer cell response to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Modified vaccinia virus Ankara can activate NF-kappaB transcription factors through a double-stranded RNA-activated protein kinase (PKR)-dependent pathway during the early phase of virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Poxvirus protein N1L targets the I-kappaB kinase complex, inhibits signaling to NF-kappaB by the tumor necrosis factor superfamily of receptors, and inhibits NF-kappaB and IRF3 signaling by toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Adjuvant activity of type I interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Antiviral actions of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Interferon type I responses in primary and secondary infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The antitumor and immunoadjuvant effects of IFN-alpha in combination with recombinant poxvirus vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The role of type I interferon production by dendritic cells in host defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Type I interferons mediate the innate cytokine response to recombinant fowlpox virus but not the induction of plasmacytoid dendritic cell-dependent adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus-mediated inhibition of type I interferon responses is a multifactorial process involving the soluble type I interferon receptor B18 and intracellular components

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Antagonizing activity of vaccinia virus E3L against human interferons in Huh7 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus-encoded elF-2α homolog abrogates the antiviral effect of interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The fowlpox virus BCL-2 homologue, FPV039, interacts with activated Bax and a discrete subset of BH3-only proteins to inhibit apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Fowlpox virus encodes a Bcl-2 homologue that protects cells from apoptotic death through interaction with the proapoptotic protein Bak.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The poxvirus p28 virulence factor is an E3 ubiquitin ligase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Shope fibroma virus RING finger protein N1R binds DNA and inhibits apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Deadly encounter: ubiquitin meets apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Functional and structural studies of the vaccinia virus virulence factor N1 reveal a Bcl-2-like anti-apoptotic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The vaccinia virus F1L protein interacts with the proapoptotic protein Bak and inhibits Bak activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus F1L interacts with Bak using highly divergent Bcl-2 homology domains and replaces the function of Mcl-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Interferon-gamma: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

An interferon-gamma-binding protein of novel structure encoded by the fowlpox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus vectors with an inactivated gamma interferon receptor homolog gene (B8R) are attenuated In vivo without a concomitant reduction in immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The genome of swinepox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Poxvirus-encoded gamma interferon binding protein dampens the host immune response to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Evaluation of recombinant fowlpox virus expressing infectious bronchitis virus S1 gene and chicken interferon-γ gene for immune protection against heterologous strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Inflammasomes as microbial sensors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

A soluble receptor for interleukin-1 beta encoded by vaccinia virus: a novel mechanism of virus modulation of the host response to infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

A mechanism for the inhibition of fever by a virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The genome of fowlpox virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Co-regulation of NF-kappaB and inflammasome-mediated inflammatory responses by myxoma virus pyrin domain-containing protein M013

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Susceptibility of different leukocyte cell types to Vaccinia virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Poxvirus tropism for primary human leukocytes and hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Poxvirus semaphorin A39R inhibits phagocytosis by dendritic cells and neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus impairs directional migration and chemokine receptor switch of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Differences and similarities in viral life cycle progression and host cell physiology after infection of human dendritic cells with modified vaccinia virus Ankara and vaccinia virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Dendritic cells are preferentially targeted among hematolymphocytes by Modified Vaccinia Virus Ankara and play a key role in the induction of virus-specific T cell responses in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Modified vaccinia virus Ankara induces moderate activation of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus proteins activate human dendritic cells to induce T cell responses in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Comparing human T cell and NK cell responses in viral-based malaria vaccine trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Recombinant fowlpox virus elicits transient cytotoxic T cell responses due to suboptimal innate recognition and recruitment of T cell help

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The Canarypox-virus vaccine vector ALVAC triggers the release of IFN-gamma by Natural Killer (NK) cells enhancing Th1 polarization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

The evolving role of dendritic cells in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Subdominant CD8+ T-cell responses are involved in durable control of AIDS virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Adjuvanting a DNA vaccine with a TLR9 ligand plus Flt3 ligand results in enhanced cellular immunity against the simian immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

CpG-DNA protects against a lethal orthopoxvirus infection in a murine model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Expression of CCL20 and granulocyte-macrophage colony-stimulating factor, but not Flt3-L, from modified vaccinia virus ankara enhances antiviral cellular and humoral immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Construction and immunogenicity of recombinant fowlpox vaccines coexpressing HA of AIV H5N1 and chicken IL18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Immune responses of pigs inoculated with a recombinant fowlpox virus coexpressing GP5/GP3 of porcine reproductive and respiratory syndrome virus and swine IL-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

IL-12 and IL-18 act in synergy to clear vaccinia virus infection: involvement of innate and adaptive components of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

A multi-valent vaccinia virus-based tuberculosis vaccine molecularly adjuvanted with interleukin-15 induces robust immune responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

Interleukin-15 mediates potent antiviral responses via an interferon-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERV.11.121

21 January 2018

Identifiers

DOI

10.1586/ERV.11.121

1 reference

25 August 2017

1 reference

PubMed ID

21988308